| 29/06 | US Futures Marginally Higher Ahead of Final Q1 GDP Reading |  |
| 27/06 | ARGENX : Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patien.. | |
| 27/06 | Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. | |
| 24/06 | Argenx Gets Positive CHMP Opinion for Generalized Myasthenia Gravis Drug | |
| 24/06 | Argenx Gets EU Committee's Positive Opinion For Generalized Myasthenia Gravis Treatment | |
| 24/06 | argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. | |
| 24/06 | Argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patie.. | |
| 17/06 | European ADRs Move Lower in Friday Trading | |
| 16/06 | TRANSCRIPT : Argenx SE Presents at Goldman Sachs 43rd Annual Global Healthcare Conference,.. | |
| 07/06 | European ADRs Move Higher in Tuesday Trading | |
| 03/06 | European ADRs Move Lower in Friday Trading | |
| 01/06 | argenx to Present at Upcoming Investor Conferences | |
| 01/06 | Argenx to Present at Upcoming Investor Conferences | |
| 31/05 | Argenx's Generalized Myasthenia Gravis Therapy Gets Positive Scientific Opinion By UK W.. | |
| 31/05 | argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M.. | |
| 31/05 | Argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized M.. | |
| 19/05 | argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B.. | |
| 19/05 | argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin B.. | |
| 19/05 | Argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Ski.. | |
| 13/05 | ACTUALIZACIÓN DE LAS GRANDES EVOLUCI : final de la semana en verde |  |
| 13/05 | European ADRs Move Higher in Friday Trading | |
| 13/05 | POINT SUR LES FORTES VARIATIONS DU J : fin de semaine dans le vert |  |
| 13/05 | POINT SUR LES FORTES VARIATIONS DU J : Somfy remercie MSCI, UCB maudit la FDA | |
| 13/05 | Ça va piquer, mais on n'a pas le choix | |
| 13/05 | AVIS D'ANALYSTES DU JOUR : TotalEnergies, Roche, Ubisoft, ArgenX, SMA Solar, SoftwareOne, .. | |
| 11/05 | TRANSCRIPT : Argenx SE Presents at Bank of America 2022 Healthcare Conference, May-11-2022.. | |
| 11/05 | Investitionen verhageln Evotec das Ergebnis - Aktie im Sinkflug |  |
| 10/05 | argenx announces results of Annual General Meeting of Shareholders | |
| 10/05 | Argenx announces results of Annual General Meeting of Shareholders | |
| 10/05 | European ADRs Move Higher in Tuesday Trading | |
| 05/05 | SECTOR UPDATE : Health Care Stocks Tumbling in Late Trade | |
| 05/05 | SECTOR UPDATE : Health Care Stocks Dropping in Afternoon Trade | |
| 05/05 | Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART(R).. | |
| 05/05 | European ADRs Decline in Thursday Trading | |
| 05/05 | SECTOR UPDATE : Health Care Stocks Decline Premarket Thursday | |
| 05/05 | TRANSCRIPT : Argenx SE, Q1 2022 Earnings Call, May 05, 2022 | |
| 05/05 | POINT SUR LES FORTES VARIATIONS DU J : mini-séisme pour CGG, Airbus à haute altitude | |
| 05/05 | Argenx Says Vyvgart Drug Improved Platelet Count in Patients With Bleeding Disorder | |
| 05/05 | Argenx Q1 Loss Widens | |
| 05/05 | Argenx's Bleeding Disorder Drug Improves Platelet Count in Late-Stage Study | |
| 05/05 | Argenx Forecasts $1 Billion Cash Utilization in FY22 | |
| 05/05 | argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alf.. | |
| 05/05 | argenx Reports First Quarter 2022 Financial Results and Provides Business Update | |
| 05/05 | Argenx Reports First Quarter 2022 Financial Results and Provides Business Update | |
| 05/05 | Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alf.. | |
| 05/05 | Argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod .. | |
| 05/05 | Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 04/05 | argenx to Present at BofA Securities 2022 Healthcare Conference | |
| 04/05 | Argenx to Present at BofA Securities 2022 Healthcare Conference | |
| 28/04 | ARGENX : argenx to Report First Quarter 2022 Financial Results and Business Update on May .. | |
| 28/04 | Argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 20.. | |
| 22/04 | BB Biotech plombé au 1er trimestre par des marchés capricieux | |
| 05/04 | Argenx SE Says Long-Term Vyvgart Treatment Reduces Generalized Myasthenia Gravis Sympto.. | |
| 05/04 | Argenx's Myasthenia Gravis Drug Shows Improved Disease Scores In Late-stage Extension T.. | |
| 05/04 | Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA.. | |
| 05/04 | Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGA.. | |
| 01/04 | argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American .. | |
| 01/04 | Argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American .. | |
| 30/03 | Argenx's Capital Raise Grows To $805 Million After Underwriters Exercise Option | |
| 29/03 | Argenx announces full exercise of underwriters' option to purchase additional ADSs | |
| 29/03 | Argenx announces Annual General Meeting of Shareholders on May 10, 2022 | |
| 29/03 | Argenx Raises $700 Million Via Share Issue | |
| 28/03 | argenx announces closing of global offering | |
| 25/03 | ARGENX : announces launch of proposed global offering - Form 6-K | |
| 24/03 | Argenx Prices $700 Million Global Offering | |
| 24/03 | Argenx Prices $700 Million Global Offering | |
| 24/03 | Argenx raises $700 million in gross proceeds in a global offering | |
| 23/03 | Argenx Initiates $500 Million Global Share Offering | |
| 22/03 | Argenx Launches $500 Million Stock Offering; Shares Down 4% After Hours | |
| 22/03 | argenx announces launch of proposed global offering | |
| 22/03 | SECTOR UPDATE : Health Care Stocks Mixed on Tuesday | |
| 22/03 | Halozyme Therapeutics Says Argenx's Phase 3 Trial in Generalized Myasthenia Gravis Meet.. | |
| 22/03 | ARGENX : Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneo.. | |
| 22/03 | Argenx SE Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcut.. | |
| 22/03 | TRANSCRIPT : Argenx SE - Special Call | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
Rapport
